Results 121 to 130 of about 17,785 (168)

Stearic acid-modified PSMA-targeting peptide-drug conjugate for long-acting prostate cancer therapy. [PDF]

Chem Sci
Qiu Z, Zheng X, Pan S, Zhong Y, Chen X, Wen X, Chen X, Li S, Cheng H, Chen X.   +9 more
europepmc   +1 more source

First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach. [PDF]

Mol Imaging Radionucl Ther
Amnuaywattakorn S, Charoenphun P, Ativitavas T, Pasawang P, Khamwan K, Thongpraparn T, Khiewvan B, Ruangma P, Chamroonrat W, Chuamsaamarkkee K.   +9 more
europepmc   +1 more source

Estimation of split renal function using [¹⁸F]-flotufolastat PET/CT compared with [⁶⁸Ga]-PSMA-11 and [^99mTc]-MAG3 scintigraphy. [PDF]

EJNMMI Res
Gammel MCM, Olufs C, Hansen K, Brosch-Lenz J, Heck M, Weber WA, Eiber M, Rauscher I.   +7 more
europepmc   +1 more source

Correction: Jalloul et al. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management. <i>Pharmaceuticals</i> 2025, <i>18</i>, 1215. [PDF]

Pharmaceuticals (Basel)
Jalloul W, Ghizdovat V, Pócza T, Saviuc A, Jalloul D, Grierosu IC, Stefanescu C.   +6 more
europepmc   +1 more source

Autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA [PDF]

, 2020
openaire   +1 more source

A comparison of dimensionality reduction approaches for pre-treatment PSMA-PET/CT radiomics in prostate adenocarcinoma outcome prediction. [PDF]

Radiat Med Prot
Singh A, Mendes WS, Oh SB, Guler OC, Elmali A, Demirhan B, Sawant A, Tran P, Onal C, Ren L.   +9 more
europepmc   +1 more source